OncoMatch/Clinical Trials/NCT06492837
Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients
Is NCT06492837 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Mosunetuzumab in combination with Zanubrutinib for follicular lymphoma.
Treatment: Mosunetuzumab in combination with Zanubrutinib — This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD20 overexpression (positive by flow cytometry or immunohistochemistry)
cFL (CD20+ by flow cytometry or immunohistochemistry)
Disease stage
Excluded: Stage I, II
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: anti-CD20 antibody — systemic therapy
At least one and up to three lines of systemic therapy containing an anti-CD20 antibody (anti-CD20 alone and/or in combination with radiotherapy is not considered as a line of therapy).
Cannot have received: Bruton's tyrosine kinase inhibitor
Prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor (BTKi).
Cannot have received: anti-CD20xCD3 bispecific antibody
Prior exposure to an anti-CD20xCD3 bispecific antibody (bsAbs).
Cannot have received: allogeneic hematopoietic stem cell transplantation
Prior allogeneic hematopoietic stem cell transplantation.
Cannot have received: CAR-T cell therapy
Exception: within 90 days prior to first therapy administration
Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 90 days prior to first therapy administration.
Lab requirements
Blood counts
ANC > 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L; Hemoglobin ≥ 9 g/dL
Kidney function
creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula, normalized to 1.72 m2)
Liver function
AST and ALT ≤ 2.5 x ULN; Bilirubin ≤1.5 x ULN (unless due to Gilbert's syndrome or non-hepatic origin)
Adequate hematological counts defined as follows: Absolute neutrophil count (ANC) > 1.0 x 10^9/L; Platelet count ≥ 75 x 10^9/L; Hemoglobin ≥ 9 g/dL. Adequate renal function defined as creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula, normalized to 1.72 m2). Adequate hepatic function per local laboratory reference range as follows: AST and ALT ≤ 2.5 x ULN; Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify